XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development
SHANGHAI, Nov. 5, 2025 /PRNewswire/ -- Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and...
XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform
CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and...
XtalPi Announces Strategic Acquisition of Liverpool ChiroChem (LCC), Unlocking Unprecedented Power in Chemical Space Exploration
CAMBRIDGE, Mass. and LIVERPOOL, United Kingdom, June 13, 2025 /PRNewswire/ -- XtalPi, a leading life sciences and new materials R&D platform powered by quantum physics, AI and robotics, today announced its acquisition of Liverpool ChiroChem...
XtalPi and Kula Bio Forge Multi-Million USD Collaborative R&D Agreement to Advance AI-Driven Microbial Fertilizers in China and the Middle East
CAMBRIDGE, Mass., March 28, 2025 /PRNewswire/ -- XtalPi (2228.HK) today announced the official signing of a strategic R&D collaboration agreement with U.S.-based Kula Bio in Boston. This partnership initiates a joint research initiative worth...
UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform
Computational advancements enable earlier and more widespread use of antibody-antigen structural insights across drug discovery process These advancements have the potential to transform antibody discovery methods, broadening therapeutic...